Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53

Leukemia and Lymphoma

Volumn 50, Issue 3, 2009, Pages 455-456

  Sanchez Gonzalez, Blanca ^a   Garcia, Mar ^a   Serrano, Sergi ^a   Besses, Carles ^a   Salar, Antonio ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GEMCITABINE; IBRITUMOMAB TIUXETAN; MITOXANTRONE; OXALIPLATIN; PREDNISOLONE; PREDNISONE; PROTEIN P53; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; NITROGEN MUSTARD COMPOUNDS; RECURRENCE; REMISSION INDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67650902374     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802684342     Document Type: Article

References (10)

1. Balfour, J. A. and Goa, K. L. (2001) Bendamustine. Drugs, 61, pp. 631-638.
2. Bremer, K. (2002) High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol, 128, pp. 603-609.
3. Rummel, M. J., Al-Batran, S. E. Zim, S. et al. (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol, 23, pp. 3383-3389.
4. Weide, R., Hess, G. Koppler, H. et al. (2007) High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma, 48, pp. 1299-1306.
5. Friedberg, J. W., Cohen, P. Chen, L. et al. (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol, 26, pp. 204-210.
6. Herold, M., Schulze, A. Niederwieser, D. et al. (2006) Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: Results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol, 132, pp. 105-112.
7. Hiddemann, W., Kneba, M. Dreling, M. et al. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, pp. 3725-3732.
8. Witzig, T. E., Flinn, I. W. Gordon, L. I. et al. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 20, pp. 3262-3269.
9. Stiewe, T. (2007) The p53 family in differentiation and tumorigenesis. Nat Rev Cancer, 7, pp. 165-168.
10. Knoops, L. and de Jonq, P. (2008) The role of the p53 pathway in the treatment of follicular lymphoma. Cell Cycle, 7, pp. 436-439.